| Cat. No. |
Product Name |
Information |
| PC-25853 |
NSC228155
EGFR activator, CREB-CBP inhibitor
|
NSC228155 (NSC 228155) is a potent inhibitor of CREB-CBP interaction (IC50=0.36 uM) taregting interaction of kinase-inducible domain (KID) from CREB and KID-interacting domain (KIX) from CBP, also is an activator of EGFR, binds to the extracellular region of EGFR and enhances tyrosine phosphorylation of EGFR. |
| PC-25509 |
Tarloxotinib
pan-HER inhibitor
|
Tarloxotinib (TH-4000) is a hypoxia-activated pan-HER inhibitor, generates the active form TH-4000Effector (TH-4000E) under hypoxic condition, TH-4000E selectively inhibits EGFR, HER2 and HER4 with IC50 of <1 nM. |
| PC-24940 |
Genistein
Hsp90β inhibitor
|
Genistein (NPI 031L) is a soy isoflavone and multiple tyrosine kinases (e.g., EGFR, MKK4 (IC50=400 nM)) inhibitor, Genistein is a chemotherapeutic agent against different types of cancer. |
| PC-24922 |
EGFR-targeting peptide GE11
EGFR ligand
|
EGFR-targeting peptide GE11 is an epidermal growth factor receptor (EGFR)-specific ligand for active targeting of EGFR-overexpressing cancer cells, Conjugation of GE11 peptides to liposomal constructs enhances anti-tumor efficacies and specificities in laryngeal cancer cells. |
| PC-24432 |
ErbB4 receptor agonist E4A
ErbB4 agonist
|
ErbB4 receptor agonist E4A is a small molecule ErbB4 receptor agonist, activates ErbB4 receptor and prevents neuronal senescence induced by D-Galactose through inhibition of the ferroptosis pathway. |
| PC-24172 |
YK-029A
mutant EGFR inhibitor
|
Pruvonertinib (YK-029A) is potent, wild-type sparing and mutant-selective inhibitor of EGFR T790 M and exon 20 insertion mutations with IC50 of 0.37 nM (EGFR L858R/T790 M), 29-fold selective over EGFR wt. |
| PC-24110 |
Andamertinib
EGFR inhibitor
|
Andamertinib (PLB1004, PLB-1004) is a potent, selective and irreversible inhibitor of EGFR exon 20 insertion mutations with IC50 values ranging from 25.67-316.6 nM. |
| PC-24040 |
DA-0157
EGFR/ALK inhibitor
|
DA-0157 (DAJH-1050766) is a potent, dual inhibitor targeting EGFR C797S mutation, ALK-positive, and EGFR/ALK co-mutations with IC50 of 6.9 nM, 5.5 nM and 7.4 nM for EGFRDel19/T790M/C797S, ALK-WT and ALK-L1196M in Ba/F3 cell assays, respectively. |
| PC-23954 |
AZ14245445
EGFR Ex20Ins inhibitor
|
AZ14245445 is a potent, selective, and brain-penetrant inhibitors of EGFR Ex20Ins mutants with pIC50 of 7.9 in cellular SVD, (EGFR D770_N771insSVD) assays. |
| PC-23953 |
AZ14240475
EGFR Ex20Ins inhibitor
|
AZ14240475 is a potent, selective, and brain-penetrant inhibitors of EGFR Ex20Ins mutants with pIC50 of 7.6 in cellular SVD, (EGFR D770_N771insSVD) assays. |
| PC-23843 |
Canertinib
pan-ErbB inhibitor
|
Canertinib (CI-1033, PD183805) is a potent, irreversible, orally available pan-ErbB inhibitor for EGFR and ErbB2 with IC50 of 7.5 nM and 9.0 nM in autophosphorylation assay. |
| PC-23647 |
BBT-176
EGFR C797S inhibitor
|
BBT-176 is a potent, mutant-selective fourth-generation inhibitor of EGFR C797S mutations with IC50 of 4.36, 1.79, and 5.35 nM for EGFR 19Del/C797S, EGFR 19Del/T790M/C797S, and EGFR L858R/C797S, respectively. |
